S&P 500   3,206.29 (-0.63%)
DOW   26,719.23 (-0.56%)
S&P 500   3,206.29 (-0.63%)
DOW   26,719.23 (-0.56%)
S&P 500   3,206.29 (-0.63%)
DOW   26,719.23 (-0.56%)
S&P 500   3,206.29 (-0.63%)
DOW   26,719.23 (-0.56%)
Log in

United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,179,100.00 in Stock

Last updated on Wednesday, July 8th, 2020 by MarketBeat

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 10,000 shares of United Therapeutics stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $117.91, for a total transaction of $1,179,100.00. Following the sale, the chief executive officer now directly owns 10,140 shares of the company's stock, valued at $1,195,607.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

NASDAQ UTHR traded down $0.82 during trading on Wednesday, reaching $117.78. The company's stock had a trading volume of 361,000 shares, compared to its average volume of 628,976. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.46 and a current ratio of 8.91. The firm has a market cap of $5.24 billion, a price-to-earnings ratio of 9.82 and a beta of 0.86. United Therapeutics Co. has a twelve month low of $74.31 and a twelve month high of $127.79. The business's fifty day moving average price is $119.68 and its 200-day moving average price is $103.18.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.12 EPS for the quarter, beating analysts' consensus estimates of $2.43 by $0.69. The company had revenue of $356.30 million for the quarter, compared to analyst estimates of $343.68 million. United Therapeutics had a net margin of 36.59% and a return on equity of 19.19%. United Therapeutics's quarterly revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the business posted $3.58 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Co. will post 10.4 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. Amundi Pioneer Asset Management Inc. increased its stake in United Therapeutics by 18.8% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 76,221 shares of the biotechnology company's stock valued at $8,945,000 after purchasing an additional 12,087 shares during the period. Victory Capital Management Inc. increased its stake in shares of United Therapeutics by 3.0% during the fourth quarter. Victory Capital Management Inc. now owns 10,493 shares of the biotechnology company's stock worth $924,000 after acquiring an additional 304 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of United Therapeutics by 9.7% during the fourth quarter. Envestnet Asset Management Inc. now owns 9,839 shares of the biotechnology company's stock worth $867,000 after acquiring an additional 874 shares during the period. Great West Life Assurance Co. Can acquired a new position in shares of United Therapeutics during the fourth quarter worth about $1,878,000. Finally, Panagora Asset Management Inc. increased its stake in shares of United Therapeutics by 20.6% during the fourth quarter. Panagora Asset Management Inc. now owns 1,287 shares of the biotechnology company's stock worth $113,000 after acquiring an additional 220 shares during the period. Institutional investors own 98.11% of the company's stock.

Several research firms have recently issued reports on UTHR. HC Wainwright lifted their price objective on shares of United Therapeutics from $85.00 to $125.00 and gave the stock a "neutral" rating in a research report on Thursday, June 25th. Zacks Investment Research raised shares of United Therapeutics from a "hold" rating to a "buy" rating and set a $128.00 price objective for the company in a research report on Sunday, May 3rd. Cowen reaffirmed a "buy" rating and set a $145.00 price objective on shares of United Therapeutics in a research report on Friday, June 12th. TheStreet raised shares of United Therapeutics from a "c" rating to a "b" rating in a research report on Wednesday, April 29th. Finally, Wedbush reissued a "buy" rating and issued a $243.00 price target on shares of United Therapeutics in a research report on Thursday, June 25th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company's stock. The company presently has a consensus rating of "Buy" and an average target price of $137.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Further Reading: What is meant by a buy rating?

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

8 Artificial Intelligence Stocks That Will Make You Feel Like a Smart Investor

In 2018, it was cannabis. In 2019, it was 5G. And yet before either of those trends, artificial intelligence (or AI) was growing relentlessly and undeniably.

Artificial intelligence stems from the simple fact that computers are getting smarter. And they are being designed to process information faster. The words “machine learning” are being used to summarize the creation of algorithms, freed from human programmers, which train themselves on massive data sets. Earlier this year, two separate artificial intelligence “machines” demonstrated the ability to “read” Wikipedia entries and answer questions better than humans did.

But AI is more than a parlor trick. Chances are at some point today, you’ve experienced a benefit of artificial intelligence. You may have gotten to this page because of an internet search. You may have asked Alexa or your Google Assistant to perform a command. You may have voice-activated your Roomba vacuum. You may have used an AI-powered GPS system to get to wherever you’re reading this.

In the future, you may be hailing an autonomous car. A virtual assistant will be able to place calls for you to make appointments. But instead of sounding like a robot, the assistant will sound human, with an understanding of context and nuance. And those are just two applications. There will be more because the possibilities of artificial intelligence are expansive. But they can also be somewhat chilling. Many of the functions that are performed by humans today may be made obsolete by AI. But that’s a subject for another day.

Right now, you want to know how you can profit from this emerging trend.

You’ve come to the right place. In this special presentation, we will take a look at 8 stocks that can help you profit from the artificial intelligence trend.

View the "8 Artificial Intelligence Stocks That Will Make You Feel Like a Smart Investor".

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.